Connect with us

Health

Global Health Leaders Urge Broadened Research Strategy To Prepare For Next Pandemic

Published

on

Global Health Leaders Urge Broadened Research Strategy To Prepare For Next Pandemic

The Coalition for Epidemic Preparedness Innovations (CEPI) and the World Health Organization (WHO) have issued a joint call for a broader research strategy to prepare for the next pandemic. The appeal, made at the Global Pandemic Preparedness Summit 2024 in Rio de Janeiro, Brazil, emphasizes the need for a more comprehensive approach to understanding and addressing the threat of emerging pathogens.

Currently, research tends to focus on individual pathogens with known pandemic potential. However, CEPI and WHO are advocating for a more expansive approach that encompasses entire families of pathogens, regardless of their perceived pandemic risk. This strategy involves using prototype pathogens as guides to develop knowledge and countermeasures that can be rapidly adapted to emerging threats.

The updated recommendation is likened to expanding the “lighted area” of knowledge, moving beyond well-studied pathogens to encompass a broader range of potential threats. This includes regions of the world with high biodiversity and limited research infrastructure, where novel pathogens may be lurking. By adopting this approach, scientists can gain a deeper understanding of how pathogens transmit and infect humans, and how the immune system responds.

The call to action is backed by a report from the WHO R&D Blueprint for Epidemics, which involved over 200 scientists from more than 50 countries. The report evaluated the science and evidence on 28 virus families and one core group of bacteria, encompassing 1652 pathogens. CEPI and WHO are urging globally coordinated, collaborative research to prepare for potential pandemics, with a focus on equitable participation from researchers around the world.

To facilitate this, WHO is establishing Collaborative Open Research Consortia (CORCs) for each pathogen family, with a WHO Collaborating Centre acting as the research hub. These CORCs will bring together researchers, developers, funders, regulators, and trial experts to promote greater research collaboration and equitable participation.

As WHO Director-General Dr Tedros Adhanom Ghebreyesus emphasized, “History teaches us that the next pandemic is a matter of when, not if. We need to come together as a global community to prepare for the next pandemic, advancing our knowledge of the many pathogens that surround us.” By adopting a broader research strategy, we can bolster our ability to swiftly respond to unforeseen variants, emerging pathogens, and unknown threats.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Health

Trump Proposes Five-Way Split of Childhood Vaccines

Published

on

Trump Congratulates UK’s Farage, Ignores Starmer

Trump Proposes Five-Way Split of Childhood Vaccines

 

President Donald Trump has proposed splitting some childhood vaccines into five separate doses administered six months apart, a plan that vaccine experts say could leave children inadequately protected if the individual doses contain too little vaccine.

 

Trump made the proposal on Friday while speaking about his administration’s plans to alter the United States childhood immunisation schedule.

 

He said children could receive doses labelled one through five, with each containing what he described as about 20 per cent of the usual amount.

 

“Instead of a child going in and having a tremendous amount of different vaccines pumped into a big proportion of the body … we’re going to recommend that they do five doses marked one, two, three, four, five and that they be given in six-month intervals,” Trump said.

 

Trump did not identify all the vaccines that would be affected. He specifically referred to the polio vaccine, which he described as having been “amazing”.

 

However, vaccine specialist Dr Paul Offit, director of the Vaccine Education Centre at the Children’s Hospital of Philadelphia, said the proposed approach would not provide the intended protection.

 

Offit explained that vaccines are developed through dose-response studies to determine the smallest quantity capable of producing a protective immune response.

 

“You don’t want to give too much, where you know you don’t need all that, and you don’t want to give too little,” he said.

 

He told CNN that administering vaccines at doses below the level required to generate an immune response could make them ineffective rather than safer.

 

Trump also linked the proposed changes to autism, saying he expected them to lead to a “massive reduction” in autism.

 

However, decades of scientific research have found no causal link between childhood vaccines and autism.

 

The President’s comments came amid broader efforts by his administration to alter federal childhood vaccination policy.

 

In August, Trump signed an executive order seeking changes to the childhood immunisation schedule, including separating the measles, mumps and rubella vaccine into individual shots.

 

The administration has argued that the changes would reduce the number of vaccines given to children and address concerns about the existing schedule.

 

Health and Human Services Secretary Robert F. Kennedy Jr., who was with Trump as he outlined the proposal, has also backed changes to federal vaccine policy.

 

Kennedy spoke on Thursday at a conference organised by Children’s Health Defense, an organisation associated with vaccine scepticism.

Continue Reading

Health

DRC gets 70,000 Ebola vaccine doses as trial targets Bundibugyo virus 

Published

on

WHO Releases New Guidelines for HIV Prevention

DRC gets 70,000 Ebola vaccine doses as trial targets Bundibugyo virus 

 

The Democratic Republic of Congo has received 70,000 doses of the Ervebo Ebola vaccine from the global vaccine stockpile as health authorities intensify efforts to contain an outbreak of Bundibugyo virus disease.

 

The doses were released by the International Coordinating Group on Vaccine Provision following a request from the DRC government last week.

 

The development comes amid uncertainty over the effectiveness of Ervebo against the Bundibugyo strain, which is different from the Zaire ebolavirus for which the vaccine was originally developed and licensed.

 

Of the 70,000 doses, 20,000 have been allocated for a Phase 3 clinical trial designed to assess the vaccine’s potential impact against the Bundibugyo virus, while 50,000 doses will be administered to frontline and health workers in line with recommendations from the World Health Organisation’s Strategic Advisory Group of Experts on Immunization.

 

The effectiveness of Ervebo against Bundibugyo virus in humans is currently unknown.

 

However, preliminary laboratory and animal studies have suggested that the vaccine could offer some protection, prompting researchers to investigate its potential through the clinical trial.

 

The trial is expected to generate evidence that could guide future decisions on the use of Ervebo in outbreaks involving the Bundibugyo strain.

 

Health authorities have also stressed the importance of informed consent, saying people offered the vaccine must be adequately informed about its potential risks, benefits and limitations in relation to the current outbreak.

 

The ICG is made up of the WHO, International Federation of Red Cross and Red Crescent Societies, Médecins Sans Frontières and UNICEF, while Gavi, the Vaccine Alliance, funds the global vaccine stockpile.

 

The WHO and Africa Centres for Disease Control and Prevention welcomed the allocation, supporting the DRC’s efforts to protect affected communities and contain the outbreak through a community-led response.

 

Both organisations said they would continue to support the DRC government in protecting communities, saving lives and generating scientific evidence that could strengthen Africa’s preparedness for future viral outbreaks.

 

The Bundibugyo outbreak has renewed attention on the need for effective vaccines and rapid scientific responses to emerging infectious diseases, with the outcome of the DRC trial expected to provide important information for future outbreak control.

 

Continue Reading

Health

Africa CDC, WHO demand urgent scale-up of DRC Ebola response

Published

on

WHO Releases New Guidelines for HIV Prevention

Africa CDC, WHO demand urgent scale-up of DRC Ebola response

 

The Africa Centres for Disease Control and Prevention and the World Health Organisation have called for an urgent scale-up of the community-led response to the Ebola outbreak in the Democratic Republic of the Congo.

 

The organisations said the response must focus on early detection, contact tracing, access to treatment, protection of frontline health workers and faster deployment of resources to affected communities.

 

The call followed a joint high-level mission to Uganda and the DRC on August 4 and 5, led by the WHO Director-General, Dr Tedros Adhanom Ghebreyesus; Director-General of Africa CDC, Dr Jean Kaseya; and WHO Regional Director for Africa, Dr Mohamed Janabi.

 

The delegation visited Kampala, Bunia and Kinshasa, where it held discussions with government officials, response coordinators, health workers, community representatives and development partners.

 

In Uganda, the delegation commended the country for successfully containing local transmission after it declared the end of its outbreak on July 28.

 

Uganda recorded 20 confirmed cases and two deaths, while all identified contacts completed their follow-up.

 

The organisations said Uganda’s experience demonstrated the importance of early detection, rapid contact tracing, coordinated government action, community engagement and effective cross-border surveillance.

 

However, they warned that continued transmission in the DRC meant neighbouring countries remained at risk and should maintain surveillance, laboratory readiness and cross-border coordination.

 

The delegation subsequently travelled to Bunia, the epicentre of the outbreak in Ituri Province, where it met provincial authorities, health workers, community leaders and response partners.

 

It also visited the Rwangole Ebola Treatment Centre to assess its readiness to expand access to timely and quality care.

 

The delegation stressed that communities would play a central role in containing the outbreak, urging authorities to ensure that residents receive accurate information from trusted sources and can report suspected cases and seek treatment without fear.

 

It also identified community, religious, women and youth leaders as critical partners in building confidence and ensuring that response measures reflect local realities.

Continue Reading

Trending